TylerJ.CurielMD

Oncology • Lebanon, NH

Professor, Medicine, University of Texas Medical School, San Antonio

Join to view full profile

Dr. Curiel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Curiel's full profile

Already have an account?

Office
1 Medical Center Dr
Lebanon, NH 03756
Phone+1 603-650-5747

Fax+1 210-257-1428

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 1995 - 1997
Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1990
Yale-New Haven Medical CenterInternship, Internal Medicine, 1985 - 1986
Duke University School of MedicineClass of 1982

Certifications & Licensure

NH State Medical License 2022 - 2026
CO State Medical License 1991 - 2025
TX State Medical License 2000 - 2024
LA State Medical License 2001 - 2008
CT State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer Start of enrollment: 2007 Feb 01
Completed
Phase 2
Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors Start of enrollment: 2012 Jun 01
Completed
Phase 1
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer Start of enrollment: 2009 Jun 01
Terminated
Phase 2
Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy Start of enrollment: 2012 Apr 01
Completed
Early Phase 1
Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis Start of enrollment: 2017 Jan 20
Withdrawn
Join now to see all

Publications & Presentations

PubMed

Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.
Clare E Murray, Anand V R Kornepati, Carlos Ontiveros, Yiji Liao, Bárbara de la Peña Avalos
Molecular Cancer. 2024-10-30
7 citations
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01
2 citations
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
Behnam Ebrahimi, Suryavathi Viswanadhapalli, Uday P Pratap, Gopalam Rahul, Xue Yang
NPJ Precision Oncology. 2024-05-24

Journal Articles

Suppressive IL-17A+Foxp3+ and Ex-Th17 IL-17AnegFoxp3+ Treg Cells Are a Source of Tumour-Associated Treg Cells
Robert P Edwards, Tyler Curiel, Sara Berkey, David L Bartlett, Kunle Odunsi, Nature

Press Mentions

Suppressive IL-17A+Foxp3+ and Ex-Th17 IL-17AnegFoxp3+ Treg Cells Are a Source of Tumour-Associated Treg CellsMarch 14th, 2020
Chutes & Ladders—Biogen Executive Kress Takes over the Reins of SyntimmuneJanuary 5th, 2018
Agenus Announces Key Leadership to Advance Combination Trials for Planned BLA FilingsJanuary 4th, 2018

Grant Support

Senior LeadershipNational Cancer Institute2009–2011
Planning And EvaluationNational Cancer Institute2009–2011
DevelopmentalNational Cancer Institute2009–2011
Career DevelopmentNational Cancer Institute2009–2011
Cancer Prevention And Population SciencesNational Cancer Institute2009–2011
AntibodyNational Cancer Institute2009–2011
AdministrationNational Cancer Institute2009–2011
Phase II Trial Of Ontak To Treat Ovarian Cancer Under B*Food And Drug Administration2007–2010
A Novel MAPK Family In T. GondiiNational Institute Of Allergy And Infectious Diseases2006–2010
Plasmacytoid Dendritic Cell Behavior In Ovarian CancerNational Cancer Institute2007–2009
CXCR4/SDF-1 Interactions In Ovarian Cancer PathogenesisNational Cancer Institute2007
SAN Antonio Cancer InstituteNational Cancer Institute2005–2007
A Phase II Trial Of Intravenous Ontak To Treat Epithelial Ovarian Cancer FIGONational Center For Research Resources2006
Phase II Trial Of Ontak To Treat Ovarian Cancer Under B*Food And Drug Administration2006
A Novel MAPK Family In T. GondiiNational Institute Of Allergy And Infectious Diseases2005–2006
Plasmacytoid Dendritic Cell Behavior In Ovarian CancerNational Cancer Institute2005–2006
Phase I/II Dose De-Escalation Trial Of Intravenous Ontak In Patients With CancerNational Center For Research Resources2004–2006
CXCR4/SDF-1 Interactions In Ovarian Cancer PathogenesisNational Cancer Institute2004–2006
Dendritic Cell-Mediated Anti-Tumor ImmunityNational Center For Research Resources2003–2006
Targeting SIV Nef Directly To Dendritic CellsNational Center For Research Resources2005
Dendritic Cell Targeted Hepatitis C Virus ImmunotherapyNational Institute On Drug Abuse2003
Dc-Induced Hiv-Specific T Cell ImmunityNational Institute Of Allergy And Infectious Diseases2001
Dc-Induced Hiv-Specific T Cell ImmunityNational Institute Of Allergy And Infectious Diseases2000–2001
Human Cellular Immunity To Toxoplasma GondiiNational Institute Of Allergy And Infectious Diseases1997–1999
Human Cellular Immunity To Toxoplasma GondiiNational Institute Of Allergy And Infectious Diseases1995–1996
SCID Mouse And Human Stem Cell CoreNational Institute Of Allergy And Infectious Diseases1994–1995
Cellular Immunity In AIDSNational Institute Of Allergy And Infectious Diseases1988–1989